SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicamen Biotech touches the roof on getting ANVISA Brazil nod for tablets

12 Dec 2011 Evaluate

Medicamen Biotech is currently locked at its upper circuit limit of Rs. 16.15, up by 0.75 points or 4.87% from its previous closing of Rs. 15.40 on the BSE.

The scrip opened at Rs. 15.90 and has touched a high and low of Rs. 16.15 and Rs. 15.90 respectively. So far 19287 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 38.10 on 17-Oct-2011 and a 52 week low of Rs. 14.05 on 23-Nov-2011.

Last one week high and low of the scrip stood at Rs. 19.70 and Rs. 15.40 respectively. The current market cap of the company is Rs. 12.15 crore.

The promoters holding in the company stood at 34.84% while Non-Institutions held 65.16%.

Medicamen Biotech has received an ANVISA Brazil approval for Non Beta Lactum solid tablets and coated tablets manufactured at its plant situated at Bhiwadi in Rajasthan vide resolution 5397 No RE of December 02, 2011, officially published in the gazzatte on December 05, 2011 valid for 2 years.

Medicamen Biotech manufactures pharmaceutical formulations for the Indian and overseas markets. Its product range consists of antibiotics, anti-fungicides, anti-diabetics, anti-tuberculosis, tranquillisers, laxatives, anti-asthmatics, and anti-depressants.

Medicamen Biotech Share Price

292.55 0.00 (0.00%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.00
Dr. Reddys Lab 1308.00
Cipla 1371.05
Zydus Lifesciences 943.30
Lupin 2461.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×